Nastech Pharmaceutical Co. said Thursday that it filed with the Securities and Exchange Commission to issue up to $125 million in common stock from time to time.

The company said while it has no current plans to sell the shares, the shelf registration statement filed with the SEC would allow it to do so in the future.

Proceeds from any future sale would be used for general corporate purposes, including the funding of clinical research and development programs, clinical development of product candidates, capital expenditures and working capital needs, the company said.

Nastech helps develop medications that can be administered by inhaling them. The company is developing an osteoporosis drug and recently received a federal grant to develop influenza treatments.

Shares of Nastech fell 15 cents to $16.81 in after-hours activity on the INET electronic exchange, after closing up 2 cents at $16.96 on the Nasdaq.